Abstract
Folliculotropic mycosis fungoides (FMF) is an uncommon and potentially aggressive form of cutaneous T cell lymphoma (CTCL). Phototherapy, radiotherapy, and systemic chemotherapy are the most commonly employed treatment options, but may have limited success and common adverse reactions. Bexarotene gel is a topical retinoid X receptor (RXR) agonist with activity on the follicular unit that has not been previously reported in the management of FMF. The case of a 73-year-old male with FMF that responded to bexarotene gel is presented.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 169-171 |
| Number of pages | 3 |
| Journal | Journal of Drugs in Dermatology |
| Volume | 7 |
| Issue number | 2 |
| State | Published - Feb 1 2008 |
ASJC Scopus subject areas
- Dermatology